There is no specific weight or BMI requirement for Ozempic itself, because the FDA approved it for type 2 diabetes, not weight loss. However, many doctors prescribe Ozempic off-label for weight management, and when they do, they typically follow the same BMI thresholds used for FDA-approved weight loss medications: a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition.
Why Ozempic Doesn’t Have a Weight Cutoff
Ozempic (semaglutide) is FDA-approved for three things: improving blood sugar control in adults with type 2 diabetes, reducing cardiovascular risk in adults with type 2 diabetes and heart disease, and protecting kidney function in adults with type 2 diabetes and chronic kidney disease. None of these approvals mention BMI or body weight as a qualifying factor. If you have type 2 diabetes, your doctor can prescribe Ozempic regardless of how much you weigh.
The confusion comes from the fact that Ozempic causes significant weight loss as a side effect, and many doctors now prescribe it specifically for that purpose. That’s considered “off-label” use, meaning it’s legal and common but not what the FDA reviewed and approved the drug for. When prescribing off-label for weight loss, most doctors apply the eligibility standards from Wegovy, which is the same active ingredient (semaglutide) at a higher dose and is FDA-approved for weight management.
The BMI Thresholds Most Doctors Use
For weight loss purposes, the standard criteria break into two tiers:
- BMI of 30 or higher: This qualifies you on its own, with no additional conditions required. A BMI of 30 is the clinical threshold for obesity. For reference, that’s roughly 180 pounds at 5’5″ or 210 pounds at 5’9″.
- BMI of 27 to 29.9: You can qualify at this level if you also have at least one weight-related health condition, such as high blood pressure, high cholesterol, type 2 diabetes, sleep apnea, or heart disease.
Below a BMI of 27, most providers will not prescribe semaglutide for weight loss, and insurance companies almost certainly won’t cover it. That said, if you have type 2 diabetes, BMI is irrelevant to the Ozempic prescription itself.
Ozempic vs. Wegovy: Same Drug, Different Approval
Ozempic and Wegovy both contain semaglutide. The key difference is that Wegovy comes in a higher maximum dose and carries the FDA’s approval for weight management in adults (and children 12 and older). Ozempic’s maximum dose is lower, and its approval covers only diabetes and related cardiovascular and kidney risks.
If your primary goal is weight loss rather than blood sugar control, Wegovy is the version your doctor would ideally prescribe. In practice, Ozempic is frequently prescribed off-label for weight loss because it’s sometimes easier to get, may have different insurance coverage, or may be more available during supply shortages. The weight loss effect is real with both, though Wegovy’s higher dose tends to produce somewhat greater results.
What Insurance Actually Covers
Coverage varies dramatically between insurance plans. Some plans cover GLP-1 medications for weight loss with prior authorization, some cover them only for diabetes, and some don’t cover them at all. Even when a plan technically covers weight loss drugs, you’ll likely need to meet those BMI thresholds and provide documentation of weight-related health conditions before approval goes through.
If your doctor prescribes Ozempic for type 2 diabetes, insurance approval is generally more straightforward because you’re using the drug for its FDA-approved purpose. If the prescription is for off-label weight loss, expect more hurdles. Some insurers require evidence that you’ve tried diet and exercise programs or other interventions before they’ll authorize a GLP-1 medication. Out-of-pocket costs without insurance can run over $1,000 per month.
BMI Isn’t the Whole Picture
BMI is a screening tool, not a perfect measure of health. The CDC notes that BMI should be considered alongside other factors. A person with a high muscle mass might have a BMI of 30 with relatively low body fat, while someone with a BMI of 26 could carry excess fat around their midsection that raises their metabolic risk.
Medical organizations have been pushing to update how obesity is defined. A newer framework combines BMI with waist circumference, waist-to-hip ratio, and evidence of conditions like elevated blood sugar or abnormal cholesterol. This broader approach could eventually change who qualifies for medications like semaglutide. For now, though, clinicians aren’t routinely using these updated criteria, and insurance companies still rely on BMI as the primary gatekeeper for coverage decisions.
If your BMI falls just below 27 but you have metabolic risk factors, it’s still worth having a conversation with your doctor. Eligibility in practice depends on the prescriber’s clinical judgment, your overall health profile, and what your insurance plan will authorize.